Related Experiment Video
Updated: Jan 10, 2026

Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System
Published on: October 22, 2020
Very low nicotine content cigarettes for smoking cessation: Examining a facilitated extinction approach and dosing
David J Drobes1, Steven K Sutton2, Melissa R Conn3
1Department of Health Outcomes and Behavior, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, United States; Department of Psychology, University of South Florida, 4202 East Fowler Ave PDC 4118G, Tampa, FL 33620, United States.
Objective:
We evaluated a behavioral intervention (facilitated extinction versus standard cessation counseling) and Very Low Nicotine Content (VLNC) reduction schedule (immediate versus gradual) for smoking cessation in a 2 × 2 design over 5 weeks prior to target quit date (TQD). The facilitated extinction strategies included maintaining the smoking rate across multiple smoking contexts to maximize extinction processes.
Method:
Treatment-seeking individuals who smoke cigarettes were randomized to one of four conditions. The initial target sample size was 208 to detect differences in abstinence two months post-treatment. Due to the study pause with the onset of the COVID-19 pandemic, we achieved a sample size of 127 (58 % female). Primary outcomes were treatment feasibility and in-treatment measures, including weekly self-reports of cigarettes per day (CPD), reinforcing effects of smoking, and cravings to smoke study cigarettes. Treatment satisfaction was assessed at TQD.
Results:
Treatment completion at 80 % supports feasibility, with a higher rate for gradual reduction groups (88 % versus 72 %, p = .026). High adherence to VLNC cigarettes across 5 weeks also supports feasibility. Mixed models found reduced craving to smoke study cigarettes (p < .001), reduced satisfaction with smoking (p < .001), and a decrease in study CPD (p < .001), with a greater decrease in CPD in immediate reduction groups (p = .006). Biochemically verified 7-day point prevalence abstinence two months post-treatment was 29 % and 31 % with missing data imputed as smoking, with no group differences. Overall high treatment satisfaction (M=3.8 out of 4) supports acceptability.
Conclusions:
These findings suggest VLNC cigarettes may aid broadly in cessation efforts and demonstrate feasibility for larger trials.
Related Concept Videos
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
CNS Depressants: Alcohol and Nicotine
Stimulants
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
Drug Dependence

